Crossmark

Evaluating optical coherence tomography (OCT) findings as potential biomarkers in central nervous system (CNS) lymphoma with or without ocular involvement

Crossref DOI link: https://doi.org/10.1186/s40942-021-00345-1

Published Online: 2021-11-24

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hassan, Muhammad

Halim, Muhammad Sohail

Afridi, Rubbia

Nguyen, Nam V.

Nguyen, Quan Dong

Sepah, Yasir J. http://orcid.org/0000-0002-0104-6284
License Information

Text and Data Mining valid from 2021-11-24

Version of Record valid from 2021-11-24
More Information

Article History

Received: 4 June 2021

Accepted: 7 November 2021

First Online: 24 November 2021

Declarations

:

: The local Institutional Review Board approved the retrospective chart review. The study was conducted in compliance with the declaration of Helsinki, US Code of Federal Regulations Title-21, and the Harmonized Tripartite Guidelines for Good Clinical Practice (1996). A inform consent waiver was obtained as this was a retrospective chart review.

: Not applicable.

: QDN is a recipient of a Physician Scientist Award from Research to Prevent Blindness, New York, NY, and serves on the Scientific Advisory Board for AbbVie, Bayer, Genentech, Regeneron, and Santen, among others. QDN also chaired the Steering Committee for the RISE and RIDE studies and was on the Steering Committee for the VISTA Study, and other studies sponsored by Genentech and Regeneron.

Document is current

Any future updates will be listed below